imatinib mesylate has been researched along with Peripheral Arterial Disease in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 7 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Buschmann, I; Dombret, H; Dörken, B; Giles, FJ; Grille, P; Haverkamp, W; Kim, TD; Labussière, H; le Coutre, PD; Levato, L; Lindhorst, R; Mirault, T; Nicolini, FE; Rea, D; Rosti, G; Schwarz, M | 1 |
| Giles, FJ; Hochhaus, A; Hong, F; le Coutre, PD; Mauro, MJ; McNeill, C; Ortmann, CE; Saglio, G; Woodman, RC | 1 |
| Lüscher, TF | 1 |
| Aichberger, KJ; Herndlhofer, S; Mitterbauer-Hohendanner, G; Schernthaner, GH; Schillinger, M; Sillaber, C; Valent, P | 1 |
| Letendre, L; Tefferi, A | 1 |
| Gambacorti-Passerini, C; Piazza, R | 1 |
| Abruzzese, E; Dombret, H; Dörken, B; Herndlhofer, S; Le Coutre, P; Rea, D; Trawinska, MM; Valent, P | 1 |
1 trial(s) available for imatinib mesylate and Peripheral Arterial Disease
| Article | Year |
|---|---|
Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in CML.
Topics: Adult; Aged; Benzamides; Blood Glucose; Cohort Studies; Constriction, Pathologic; Drug Resistance, Neoplasm; Fasting; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Peripheral Arterial Disease; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines | 2011 |
6 other study(ies) available for imatinib mesylate and Peripheral Arterial Disease
| Article | Year |
|---|---|
Peripheral artery occlusive disease in chronic phase chronic myeloid leukemia patients treated with nilotinib or imatinib.
Topics: Antineoplastic Agents; Arterial Occlusive Diseases; Benzamides; Cohort Studies; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Peripheral Arterial Disease; Piperazines; Pyrimidines | 2013 |
Rates of peripheral arterial occlusive disease in patients with chronic myeloid leukemia in the chronic phase treated with imatinib, nilotinib, or non-tyrosine kinase therapy: a retrospective cohort analysis.
Topics: Aged; Antineoplastic Agents; Arterial Occlusive Diseases; Benzamides; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Peripheral Arterial Disease; Piperazines; Pyrimidines; Retrospective Studies | 2013 |
Pulmonary embolism and pulmonary hypertension: two issues often neglected in cardiology.
Topics: Acetazolamide; Antihypertensive Agents; Humans; Hypertension, Pulmonary; Imatinib Mesylate; Oxygen; Peripheral Arterial Disease; Protein Kinase Inhibitors; Pulmonary Embolism; Randomized Controlled Trials as Topic; Thrombolytic Therapy | 2015 |
Nilotinib treatment-associated peripheral artery disease and sudden death: yet another reason to stick to imatinib as front-line therapy for chronic myelogenous leukemia.
Topics: Benzamides; Coronary Artery Disease; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Peripheral Arterial Disease; Piperazines; Protein Kinase Inhibitors; Pyrimidines | 2011 |
Choosing the right TKI for chronic myeloid leukemia: when the truth lies in "long-term" safety and efficacy.
Topics: Adult; Aged; Benzamides; Blood Glucose; Cohort Studies; Constriction, Pathologic; Coronary Artery Disease; Drug Resistance, Neoplasm; Fasting; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Peripheral Arterial Disease; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines | 2011 |
Severe peripheral arterial disease during nilotinib therapy.
Topics: Adult; Aged; Aged, 80 and over; Amputation, Surgical; Angioplasty; Antineoplastic Agents; Benzamides; Drug Administration Schedule; Drug Tolerance; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Peripheral Arterial Disease; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Retrospective Studies; Risk Factors; Severity of Illness Index; Stents | 2011 |